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1. Introduction  
There is sufficiently detailed understanding about how an automobile works such that 
starting or running the engine can be selectively disabled. Applying this analogy to 
colorectal cancer, the question researchers and clinicians ask is: can colorectal cancer be 
prevented from starting? Once started, can the disease be prevented from running? These 
two aims fall broadly into the categories of prevention and treatment respectively. Many of 
the aspects of colorectal cancer that provide focal points for clinical management of patients 
of the disease are included in Figure 1 (below). This volume provides insights into aspects of 
disease incidence and presentation, some of the advances and developments in diagnosis 
and patient management, and examines prevention and therapeutic targets and regimes. 
This chapter provides a general overview of some of the aspects of colorectal cancer that 
affect clinical management of the disease and explores incidence of the disease, diagnosis 
and treatment as well as preventive screening programs. 
2. Epidemiology 
As a disease, the statistical data for colorectal cancer are disturbing. Every year, there are 
over 1 million new cases worldwide, half of them in men; over 200,000 new cases in Europe; 
and 1.5 million new cases in the United States (Jemal et al, 2010). Over 700,000 patients die 
each year.  
Expanded surveys and studies show that the incidence of colorectal cancer is increasing 
worldwide, along with cancer detection rates. Other studies suggest that these rates may 
also be dependent on anatomic site along the intestine at which the cancer occurs. However, 
although absolute numbers of patients affected by the disease is increasing in the US, the 
trend for colorectal cancer is downward: age adjusted incidence has declined steadily since 
1976 (Ji et al, 1998; Chen et al, 2011; Eser et al, 2010; Merrill & Anderson, 2011). Genomic 
instability is present in 15% of colorectal cancer, and forms the basis for those who advocate 
the need for screening programs for colorectal cancer patients (Geiersbach et al, 2011).  
Incidence of colorectal cancer around the world per 100,000 of population varies between 3-
43 and is influenced by age, gender, socioeconomic status, and ethnicity (Center et al, 2009; 
Hao et al, 2009). Younger patients have greater susceptibility if there is an associated family 
history and tend to present at a more advanced stage of the disease. Long and short-term 
incidence of colorectal cancer is also affected by aspirin intake and this effect may be 
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dependent on dosing regime and patient history (Dube et al, 2007; Flossmann et al, 2007; 
Rothwell et al, 2010). 
 
 
Fig. 1. Basic science studies and clinical management continue to improve our 
understanding of colorectal cancer. This volume considers incidence, diagnosis and clinical 
management of the disease as well as metastatic disease. Aspects of initiation and 
mechanisms are dealt with in the first volume of the book. 
3. Diagnosis and treatment 
There has been steady improvement in survival rates in colorectal cancers that are 
diagnosed early. Prognosis for patients who present with late stages of the disease remains 
poor. Treatment options include surgery for localized tumors, chemotherapy and 
immunotherapy. When resectable, surgical removal of the tumor remains the treatment of 
choice for localized colorectal disease. Surgery may be curative or palliative and is 
sometimes combined with chemotherapeutic regimes to achieve pre-operative tumor 
shrinkage (Zhao et al, 2010). Minimally invasive approaches such as laparoscopic surgery 
for colonic tumors are reported to offer improved short-term clinical outcomes (Hiranyakas 
& Ho, 2011). Chemotherapeutic regimes include infusional combination therapies such as 
FOLFIRI that combine irinotecan, 5-fluorouracil and leucovorin, and FOLFOX that combines 
oxaliplatin, 5-fluorouracil and leucovorin (Lee & Chu, 2007; Garcia-Foncillas & Diaz-Rubio, 
2010). Studies suggest that overall survival time and progression-free survival are 
significantly improved with the addition of cetuximab to FOLFIRI. 
Better understanding of some of the molecular mechanisms in colorectal cancer has led to 
the development of targeted therapy that modulate specific pathways and pathway 
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components. Biological treatment with bevacizumab, a recombinant antibody to vascular 
endothelial growth factor (VEGF) receptor, cetuximab and panitumumab has improved 
clinical outcomes for patients, prolonged survival times and is recommended in metastatic 
disease (Koukourakis et al, 2011). Despite these improvements in treatment, the number of 
patients who develop metastatic disease is significant and the prognosis for such patients is 
poor. Metastatic disease is thought to be related to epigenetic mechanisms and the 
development of cancer stem cell-mediated chemoresistance (Anderson et al, 2011). 
Treatment for metastatic disease is complex and requires careful patient evaluation and 
selection from single and combination treatment options that include surgery for resectable 
metastases, chemotherapy and biological therapy. Fluoropyrimidine 5-fluorouracil (5-FU) 
has been joined by cetuximab, an IgG antibody whose efficacy has been documented in 
several clinical trials (Lee & Chu, 2007). Improving regimes have led to better 2-year 
survival rates in patients.  
New therapeutic approaches and targets are emerging from research studies. One 
promising approach currently being explored is the prospect of therapeutic vaccines to 
combat colorectal cancer (Kabaker et al, 2011; Kameshima et al, 2011). 
4. Screening for prevention 
A reduction in the morbidity and mortality from colorectal cancer can only be achieved 
through effective screening for the disease. Screening allows for early detection of cancer 
and early treatment of detected cancers. It is estimated that up to 60% of deaths from 
colorectal cancer could be prevented by routine screening after the age 50 years (Byers, 2011; 
He & Efron, 2011). Approaches to screening for colorectal cancer include stool-based tests 
(fecal immunochemical testing FIT, fecal occult blood testing FOBT), endoscopy 
(sigmoidoscopy and colonoscopy) and radiologic examinations (barium radiography, and 
colonography) (de Wijkerslooth et al, 2011). Studies suggest that stool-based testing is more 
cost effective than colonoscopy (Hassan et al, 2011; Wilschut et al, 2011). 
Colonoscopy remains the gold standard for screening and while it offers advantages for 
treatment such as removal of premalignant lesions, this approach may not be as protective 
for right-sided disease as it is for left sided disease (Baxter et al, 2009; Brenner et al, 2010; 
Singh et al, 2010). Other advanced colonic imaging techniques include capsule colonoscopy, 
computed tomographic colonography, virtual colonoscopy and magnetic resonance 
colonography (Liu et al, 2011). All screening programs are complicated by social and 
community factors (such as culture, level of knowledge about the disease) that affect 
participation rates (O'Donnell et al, 2010; Ramos et al, 2011; Reeder, 2011). 
5. Conclusion 
Colorectal cancer remains a major health challenge. Trends for geographically distributed 
fluctuations in incidence point towards the need for developing strategies to tackle 
increasing colorectal disease in the population under age 50 years, the relationship of the 
disease with socioeconomic status, and the increasing incidence of the disease in Asia. 
Treatment options are still dictated by the stage of the disease in the patient at presentation 
but evidence from basic science research studies are providing a better understanding of the 
disease process, drivers for improvements in therapeutic options for patients, and new 
therapeutic targets for impeding the progression of the disease. 
www.intechopen.com
 
Colorectal Cancer – From Prevention to Patient Care 
 
6 
Despite the remarkable improvement in our understanding of certain aspects of colorectal 
cancer, the best approach to combating the disease remains a preventive one. Prevention 
and screening programs need to be more efficient and more effective. Cost benefit analyses 
preclude early adoption of newer screening methods but advances in colonoscopic and 
colonographic approaches are helping to reduce morbidity and mortality for colorectal 
cancer. 
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